INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses

Background As a major driver of lymphocyte proliferation and activation interleukin 2 (IL-2) is a crucial mediator for antitumor responses. Despite promising activity in a subset of patients, wider therapeutic utility of IL-2 (aldesleukin) has been hampered by severe dose-limiting toxicities, the ex...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jason Ho, Chelsie Macedo, Garrett Cyprus, Rajay Pandit, Anya Polovina, Nadja Kern, Abrahim Hussain, Sae Jeong Ahn, William Crago, Emily Rowell, Florian J Sulzmaier, John C Timmer, Brendan P Eckelman
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMJ Publishing Group 2023-01-01
coleção:	Journal for ImmunoTherapy of Cancer
Acesso em linha:	https://jitc.bmj.com/content/11/1/e006116.full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!